Filing Analysis
Jupiter Neurosciences, Inc. has received a delisting determination from Nasdaq due to failure to maintain the minimum market value requirement. While the company has regained compliance with the $1.00 minimum bid price rule, it remains in violation of the market value rule and is appealing the decision.
🚩 Red Flags
- Delisting determination issued by Nasdaq.
- Failure to meet the $35M market value requirement for continued listing.
- Risk that an appeal may be unsuccessful, leading to permanent removal from the exchange.
📋 Key Facts
- Nasdaq issued a notice on August 27, 2026, to delist the company's common stock from the Nasdaq Capital Market.
- The delisting is due to failure to meet Nasdaq Listing Rule 5550(b)(2), which requires a minimum market value of $35,000,000.
- The company failed to regain compliance within the 180-day grace period that expired on August 25, 2026.
- The company has regained compliance with the $1.00 minimum bid price requirement (Rule 5550(a)(2)) as of August 26, 2026.
- The company intends to appeal the delisting determination via a hearing before the Nasdaq Hearings Panel.
Jupiter Neurosciences, Inc. announced that its CEO, President, CSO, and CAO have agreed to forgive a combined total of $875,315 in accrued and unpaid compensation. This debt forgiveness is intended to reduce liabilities on the company's balance sheet through gratuitous waivers by insiders.
🚩 Red Flags
- Related-party transactions: The forgiveness involves the company's primary executive officers and directors.
- Liquidity/Solvency indicator: The need for executives to forgive nearly $900k in unpaid salaries suggests significant cash flow constraints or an inability to meet payroll obligations.
- Potential 'Going Concern' precursor: While not explicitly stated, the existence of large accrued compensation liabilities that cannot be paid is a major red flag for operational viability.
📋 Key Facts
- Aggregate debt forgiven: $875,315 in accrued and unpaid compensation.
- Christer Rosén (CEO/Chairman) forgave $356,024.
- Marshall Hayward, Ph.D. (CSO) forgave $287,075.
- Alexander Rosén (CAO) forgave $150,785.
- Alison Silva (President/COO) forgave $81,431.
- The forgiveness is gratuitous; no equity or cash was issued in exchange.
- The agreements include a general release of claims by the individuals against the company and its affiliates.
Jupiter Neurosciences, Inc. completed a registered direct offering of 307,692 shares at $6.50 per share, raising approximately $2.0 million in gross proceeds. The offering was strategically timed to address Nasdaq's minimum stockholders' equity requirement.
🚩 Red Flags
- Delisting risk: The company is currently awaiting formal confirmation from Nasdaq regarding compliance with the minimum stockholders' equity rule.
- Ongoing monitoring: Nasdaq will continue to monitor equity levels; failure to maintain compliance by the next periodic report could trigger delisting.
- Micro-cap liquidity: The offering is a relatively small amount ($2M), suggesting tight capital constraints.
📋 Key Facts
- Closed a registered direct offering on August 24, 2026.
- Issued 307,692 shares of common stock at $6.50 per share.
- Total gross proceeds of approximately $2.0 million (before fees).
- The company believes this capital infusion brings stockholders' equity above the $2.5 million Nasdaq requirement.
Jupiter Neurosciences, Inc. announced a registered direct offering of 307,692 shares at $6.50 per share, aiming to raise approximately $2.0 million in gross proceeds. The company also disclosed recent share issuances under an existing Standby Equity Purchase Agreement (SEPA) with Yorkville.
🚩 Red Flags
- Frequent use of equity financing (SEPA issuances and new direct offering) suggests ongoing need for liquidity.
- The SEPA with Yorkville involves pricing at a discount to VWAP (97%), which can lead to significant dilution for existing shareholders.
📋 Key Facts
- Registered direct offering of 307,692 shares at $6.50 per share.
- Expected aggregate gross proceeds: ~$2.0 million (before fees).
- Placement agent: D. Boral Capital LLC, receiving a 7.0% cash fee plus expense reimbursement (capped at $75,000).
- Shares are being issued under an effective S-3 Registration Statement (filed April 16, 2026).
- The company recently issued 107,920 shares to Yorkville between Aug 14-21, 2026, via a SEPA at 97% of the 3-day VWAP, totaling $851,194 in proceeds.
Jupiter Neurosciences, Inc. has implemented a 1-for-75 reverse stock split effective August 6, 2026. The split is intended to consolidate shares and maintain Nasdaq compliance/trading status.
🚩 Red Flags
- Reverse stock split (typically indicates a low share price or imminent delisting risk)
- High consolidation ratio (1-for-75) suggests significant downward pressure on historical share value
📋 Key Facts
- Reverse stock split ratio: 1-for-75
- Effective Date: August 6, 2026, at 4:01 p.m. ET
- Post-split trading expected to begin on Nasdaq Capital Market on August 7, 2026
- Fractional shares will be settled in cash based on the closing price of the previous trading day
- New CUSIP number: 48208B302
- The company is an emerging growth company
Jupiter Neurosciences, Inc. disclosed the issuance and sale of 11,470,000 shares of Common Stock to Yorkville (YA II PN, Ltd.) between May 14, 2026, and July 24, 2026, under a Standby Equity Purchase Agreement (SEPA). The sales generated approximately $3.6 million in gross proceeds at a discount to VWAP.
🚩 Red Flags
- Use of a Standby Equity Purchase Agreement (SEPA), which often leads to significant shareholder dilution.
- Shares were sold at a 3% discount to the VWAP, indicating immediate downward pressure on stock price.
- High volume of shares issued relative to total outstanding (11.47M new shares vs 56.52M existing) represents ~17.8% dilution in a short period.
📋 Key Facts
- Issued and sold 11,470,000 shares of Common Stock between May 14, 2026, and July 24, 2026.
- Aggregate gross proceeds from these sales totaled approximately $3.6 million.
- The sale price was set at 97% of the lowest three-day VWAP during the pricing period.
- Total shares outstanding as of July 28, 2026, are 56,520,143.
- The transaction was conducted under a Standby Equity Purchase Agreement (SEPA) with Yorkville (YA II PN, Ltd.).
- The total capacity of the SEPA is up to $20,000,000.
Jupiter Neurosciences held its 2026 Annual Meeting of Stockholders where shareholders approved a significant reverse stock split (ratio between 1:10 and 1:100) and an increase in the 2025 Equity Incentive Plan. The filing also provides updates on outstanding convertible notes from a standby equity purchase agreement with Yorkville.
🚩 Red Flags
- Approval of a reverse stock split (ratio up to 1:100) is often used to maintain Nasdaq listing compliance or combat low share prices.
- Significant dilution risk via the SEPA and the approved increase in equity incentive plan shares.
- Reliance on convertible notes with fixed conversion prices ($1.50/share) which can lead to death-spiral-like dilution if stock price falls.
📋 Key Facts
- Annual Meeting held on July 22, 2026; quorum present at ~59% of outstanding shares.
- Shareholders approved a reverse stock split ratio between 1:10 and 1:100.
- Shareholders approved an amendment to the 2025 Equity Incentive Plan to increase available shares by 5,250,000.
- Cherry Bekaert LLC was ratified as the independent auditor for fiscal year ending Dec 31, 2026.
- $1.5 million in aggregate principal amount of Convertible Notes remains outstanding from Yorkville (YA II PN, Ltd.).
- Approximately 12.5 million SEPA Shares have been issued to date under the Standby Equity Purchase Agreement.
Jupiter Neurosciences entered into a definitive Strategic Asset License Agreement with PharmAla Biotech Holdings Inc. for the exclusive U.S. rights to develop and commercialize the ALA-002 program. The deal includes significant upfront payments, substantial milestone obligations, and equity issuance terms that include a VWAP reset mechanic.
🚩 Red Flags
- Significant potential dilution via the VWAP Reset Mechanic and equity consideration.
- Heavy contingent liabilities: up to $96.6M in total milestone payments plus royalties.
- Nasdaq 19.99% exchange cap on share issuance unless stockholder approval is obtained.
📋 Key Facts
- Upfront consideration of $3,333,333 ($1.5M cash, $1.83M in Jupiter common stock).
- Equity portion is subject to a 20-day VWAP pricing window and includes a 'VWAP Reset Mechanic' to ensure PharmAla receives full value.
- Development milestones totaling up to $23,333,333 (Phase 3 dosing and FDA approval).
- Commercialization milestones totaling up to $73,333,333 based on net sales tiers ($333M, $1B, and $2B).
- Post-milestone royalty of 3% of net sales in the Territory.
- The license is exclusive for the United States and includes sublicensing rights (with restrictions).
Jupiter Neurosciences, Inc. announced the appointment of Tomas J. Philipson, Ph.D. to its Board of Directors, effective June 26, 2026. Dr. Philipson will also serve on the Audit and Compensation Committees.
📋 Key Facts
- Appointment date: June 26, 2026
- Dr. Tomas J. Philipson appointed to Board, Audit Committee, and Compensation Committee
- Compensation includes a sign-on option for 90,000 shares vesting over 36 months
- Annual retainer/committee fees replaced by an option for 446,428 shares vesting over 36 months
- Dr. Philipson is a health care economist and former Acting Chairman of the White House Council of Economic Advisers
Jupiter Neurosciences, Inc. announced the immediate resignation of Board member Allison W. Brady from her positions on the Board, the Audit Committee, and the Compensation Committee effective June 17, 2026.
🚩 Red Flags
- Immediate departure of a committee member (Audit and Compensation) can sometimes signal internal friction, though explicitly denied in this filing.
📋 Key Facts
- Allison W. Brady resigned from the Board of Directors, Audit Committee, and Compensation Committee effective June 17, 2026.
- The resignation is not due to any disagreement with the Company regarding operations, policies, or practices.
- Her seat on the Board will remain vacant until the annual meeting scheduled for July 22, 2026.
Jupiter Neurosciences announced several compensatory arrangements, including the appointment of Alison Silva as COO and President with a salary increase to $340,200. The company also issued significant stock option grants to executives and independent directors as bonuses and performance recognition.
🚩 Red Flags
- Issuance of discretionary bonuses in stock options 'in lieu of cash' may indicate liquidity constraints, though common in micro-cap biotech.
📋 Key Facts
- Alison Silva appointed as Chief Operating Officer and President effective June 5, 2026.
- Alison Silva's base salary increased from $315,000 to $340,200.
- One-time option grants issued to Alison Silva (600,000 shares) and Saleem Elmasri (200,000 shares) for contributions.
- Independent non-employee directors each granted options to purchase up to 100,000 shares.
- Discretionary bonuses issued in stock options instead of cash to five executives, including CEO Christer Rosén (747,783 shares) and CFO Saleem Elmasri (325,565 shares).
- Most option grants vest over three years in equal quarterly installments starting September 2, 2026.
Jupiter Neurosciences, Inc. entered into a Securities Purchase Agreement on May 20, 2026, for a registered direct offering of 7,142,858 shares of common stock at $0.28 per share, aiming to raise approximately $2.0 million in gross proceeds.
🚩 Red Flags
- Highly dilutive offering of over 7.1 million shares at a very low price of $0.28 per share, indicating penny stock status and potential capital distress.
📋 Key Facts
- Entered into a Securities Purchase Agreement on May 20, 2026, with closing expected on or about May 21, 2026.
- Offering consists of 7,142,858 shares of common stock at a purchase price of $0.28 per share.
- Aggregate gross proceeds are approximately $2.0 million before fees and expenses.
- D. Boral Capital LLC acted as the placement agent, receiving a 7.0% cash fee and up to $75,000 in expense reimbursements.
- The offering is conducted under an effective Form S-3 registration statement (File No. 333-295085) declared effective on April 24, 2026.
Jupiter Neurosciences entered into a non-binding term sheet with PharmAla Biotech Holdings to acquire exclusive, perpetual U.S. rights to ALA-002, a next-generation MDMA formulation. The deal contemplates $3.33M in upfront consideration and substantial milestone payments, with a binding $600,000 escrow deposit acting as a reverse termination fee.
🚩 Red Flags
- The $600,000 escrow deposit is binding and will be forfeited to PharmAla as a reverse termination fee if a definitive agreement is not executed within 90 days.
- Substantial future cash commitments may strain the micro-cap's balance sheet.
📋 Key Facts
- Entered into a non-binding term sheet on May 19, 2026, with PharmAla Biotech Holdings for the ALA-002 program.
- Upfront consideration of $3,333,333, consisting of $1,500,000 in cash and $1,833,333 in equity (subject to a 180-day lock-up).
- Deposited $600,000 into escrow, which serves as a reverse termination fee if a definitive agreement is not signed within 90 days.
- Development milestones include $3,333,333 upon Phase 3 trial initiation and $20,000,000 upon FDA approval.
- Commercial milestones total up to $73.33M based on net sales thresholds, plus a perpetual 3% royalty.
Jupiter Neurosciences received two deficiency notices from Nasdaq on February 26, 2026, for failing to maintain the $1.00 minimum bid price and the $35 million minimum market value of listed securities (MVLS). The company has 180 days, until August 25, 2026, to regain compliance with both requirements or face potential delisting.
🚩 Red Flags
- Dual non-compliance with Nasdaq listing standards (Bid Price and Market Value).
- Explicit mention of a potential reverse stock split to regain compliance.
- Market Value of Listed Securities has eroded below the $35 million requirement.
📋 Key Facts
- Received Nasdaq notices on February 26, 2026, regarding Listing Rules 5550(a)(2) and 5550(b)(2).
- The closing bid price was below $1.00 for 30 consecutive business days from January 13, 2026, through February 25, 2026.
- The Market Value of Listed Securities (MVLS) closed below the $35 million threshold for 30 consecutive business days ended February 26, 2026.
- The company has until August 25, 2026, to regain compliance by maintaining the required thresholds for at least 10 consecutive business days.
- Management explicitly mentioned a reverse stock split as a potential option to resolve the bid price deficiency.
Jupiter Neurosciences amended its convertible promissory notes and SEPA with Yorkville (YA II PN, LTD), extending the first monthly installment payment by approximately three months to April 1, 2026, and switching to a variable payment schedule. This modification to the existing $6.0 million convertible debt facility signals potential cash flow strain at this emerging growth biotech company.
🚩 Red Flags
- Yorkville (YA II PN) is a well-known provider of toxic convertible debt to micro-cap companies; their SEPA structures are inherently dilutive to existing shareholders
- Three-month payment extension strongly suggests the company lacks sufficient cash to meet original payment obligations — a liquidity warning sign
- Shift from fixed to variable payment schedule may allow Yorkville to accelerate conversions during stock price weakness, increasing dilution
- Convertible notes with $6.0M outstanding create significant overhang and dilution risk for common shareholders
- Multiple 8-K items (1.01 and 2.03) in a single filing compounds the significance
- Certain portions of exhibits redacted under Reg S-K 601(a)(6), limiting transparency on exact conversion and payment terms
- Company is an emerging growth biotech with no evident revenue — continued reliance on structured equity/debt financing
📋 Key Facts
- Company amended convertible promissory notes originally issued under October 24, 2025 SEPA with Yorkville (YA II PN, LTD)
- Yorkville advanced up to $6.0 million to the company in two tranches via convertible promissory notes
- Omnibus Amendment dated February 20, 2026 extends first monthly installment payment to April 1, 2026 (~3 month extension)
- Payment calculation revised from prior terms to a variable payment schedule
- Company retains option to satisfy installments through cash, Advance Repayment, or combination thereof
- Advance Notice provisions under the SEPA were also updated
- Company is listed on Nasdaq Capital Market and is an emerging growth company
- Filed by CEO and Chairman Christer Rosén
Jupiter Neurosciences consummated a $1.86 million second tranche of a Pre-Paid Advance under an existing Standby Equity Purchase Agreement (SEPA) with Yorkville. This follows shareholder approval to issue shares in excess of the 19.99% Nasdaq Exchange Cap.
🚩 Red Flags
- Use of a Standby Equity Purchase Agreement (SEPA) often indicates urgent need for liquidity and can lead to significant shareholder dilution.
- Issuance of shares in excess of the 19.99% Exchange Cap is a high-dilution mechanism typically used by micro-cap companies facing capital constraints.
- The use of convertible promissory notes as part of the funding structure often includes terms that favor the lender (Yorkville) and can create downward pressure on the stock price.
📋 Key Facts
- Consummated 'Second Closing' on December 23, 2025.
- Received $1,860,000 in a second tranche of a Pre-Paid Advance from YA II PN, LTD (Yorkville).
- Shareholders approved the issuance of shares exceeding the 19.99% Nasdaq Exchange Cap on December 19, 2025.
- The SEPA allows Yorkville to purchase shares up to 100% of the average daily trading volume over the preceding five trading days.
- The transaction involved the issuance of a second convertible Promissory Note.
Jupiter Neurosciences held its 2025 Annual Meeting of Stockholders on December 19, 2025. Key outcomes included the approval of a massive increase in authorized common stock from 125 million to 500 million shares and the adoption of a new equity incentive plan.
🚩 Red Flags
- Massive increase in authorized share count (4x increase from 125M to 500M) creates significant dilution risk.
- Approval of a $20 million SEPA with Yorkville Advisors indicates a reliance on highly dilutive financing mechanisms common in micro-cap companies facing liquidity needs.
📋 Key Facts
- Annual Meeting held on December 19, 2025; quorum present at 71.68% (24,675,277 shares).
- Stockholders approved an increase in authorized Common Stock from 125,000,000 to 500,000,000 shares.
- Approved the '2025 Equity Incentive Plan' providing for 5,250,000 shares of common stock.
- Stockholders approved a proposal to comply with Nasdaq Listing Rules 5635(b) and (d), allowing issuance of up to $20 million in securities via a Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors (YA II PN, Ltd.).
- Ratified Cherry Bekaert LLC as the independent registered public accounting firm for FY 2025.
Jupiter Neurosciences, Inc. amended its 8-K to update terms of a Standby Equity Purchase Agreement (SEPA) and convertible promissory notes with Yorkville. The amendment corrects share counts and exchange caps related to the $20 million equity facility and associated debt.
🚩 Red Flags
- Highly dilutive financing structure (SEPA with a significant discount to VWAP).
- Convertible notes include 'price protection' antidilution adjustments that could further increase dilution.
- Interest rate penalty: interest jumps from 8% to 18% upon an event of default.
- The SEPA includes a variable conversion feature for Yorkville in the event of default (95% of VWAP).
- Repayment obligations on pre-paid advances create immediate cash flow pressure.
📋 Key Facts
- Entered into SEPA Amendment No. 1 on November 19, 2025, with YA II PN, Ltd. (Yorkville).
- The SEPA allows Yorkville to purchase up to $20.0 million of common stock at a discount (97% of the lowest daily VWAP over 3 days).
- Includes two tranches of convertible promissory notes totaling $6.0 million in pre-paid advances.
- First tranche ($4.0M principal) was disbursed on October 27, 2025, with a 7% OID and fixed conversion price of $1.50/share.
- Second tranche ($2.0M principal) is contingent upon registration statement effectiveness and stockholder approval.
- Notes carry an 8% annual interest rate, increasing to 18% upon default.
- The company must repay the Pre-Paid Advance in monthly installments starting 75 days after October 24, 2025.
Jupiter Neurosciences entered into a Standby Equity Purchase Agreement (SEPA) with Yorkville, allowing the company to sell up to $20 million in common stock. The deal includes $6 million in convertible promissory notes issued at a discount, featuring a fixed conversion price of $1.50 and significant dilution potential.
🚩 Red Flags
- Highly dilutive financing structure (SEPA/Death Spiral features).
- Convertible notes with a fixed conversion price ($1.50) that may be significantly higher than current market value.
- Interest rate penalty: jumps from 8% to 18% upon event of default.
- The company is obligated to file a registration statement within 30 days, indicating immediate need for capital/liquidity.
📋 Key Facts
- Entered into SEPA and Registration Rights Agreement with YA II PN, LTD (Yorkville) on October 24, 2025.
- SEPA allows for the sale of up to $20 million in common stock at a discount to VWAP (97% of lowest daily VWAP over 3 days).
- Issuance of two Convertible Notes totaling $6.0 million principal ($4.0M first tranche, $2.0M second tranche).
- First tranche of $3.72 million was disbursed on October 27, 2025.
- Convertible notes feature an Original Issue Discount (OID) of 7.0% and an interest rate of 8% (increasing to 18% upon default).
- Initial fixed conversion price for notes is $1.50 per share.
- The company must repay the notes in installments starting approximately 75 days after October 24, 2025.
Jupiter Neurosciences, Inc. has successfully regained compliance with the NASDAQ minimum bid price requirement of $1.00 per share. The company met the criteria by maintaining a closing bid price of at least $1.00 for 13 consecutive days between June 18, 2025, and July 8, 2025.
🚩 Red Flags
- Previous non-compliance with minimum bid price requirement (NASDAQ Listing Rule 5550(a)(2)).
📋 Key Facts
- The Company regained compliance with NASDAQ Listing Rule 5550(a)(2) on July 9, 2025.
- Compliance was achieved by maintaining a closing bid price of $1.00 or greater for 13 consecutive days (June 18, 2025 – July 8, 2025).
- The deficiency originally stemmed from a notice received on March 21, 2025.
- The Company had until September 17, 2025, to regain compliance.
Jupiter Neurosciences announced the approval of a bonus package for several executive officers and Titan Advisory Services. The package includes stock options and cash bonuses, with cash payments contingent upon the company maintaining over $3.5 million in cash on hand.
🚩 Red Flags
- Related-party transaction: Titan Advisory Services (an external entity) is receiving a $72,000 cash bonus.
- Contingent compensation structure linked to specific cash thresholds ($3.5M), which can sometimes be used to manage optics around liquidity.
📋 Key Facts
- Compensation Committee approved bonus packages on July 2, 2025.
- Alison Silva (CBO) granted 255,320 stock options; Saleem Elmassri (CFO) granted 102,128 stock options.
- Option exercise price set at $1.19 per share (based on July 2, 2025 closing price).
- Options have a 10-year term and vest over 3 years in equal installments.
- Cash bonuses for CEO Christer Rosén ($210k), CBO Alison Silva ($45k), CSO Marshall Hayward ($50k), CAO Alexander Rosén ($72k), and Titan Advisory Services ($72k).
- Cash payments are subject to a 'Cash on Hand Requirement' of >$3,500,000.
Jupiter Neurosciences, Inc. announced the resignation of its independent auditor, Assurance Dimensions, LLC, due to the firm discontinuing its PCAOB registrants practice. The company has simultaneously appointed Cherry Bekaert LLP as its new independent registered public accounting firm.
🚩 Red Flags
- Going concern language: Previous audit reports disclosed uncertainty regarding the Company’s ability to continue as a going concern for FY 2023 and FY 2024.
- Auditor change combined with existing going concern warnings increases risk profile.
📋 Key Facts
- Assurance Dimensions, LLC (AD) resigned effective April 16, 2025.
- Resignation reason: AD is discontinuing its PCAOB registrants practice.
- Cherry Bekaert LLP (CB) appointed as the new independent auditor effective April 16, 2025.
- Previous audit reports for FY 2023 and FY 2024 contained a 'going concern' uncertainty disclosure.
- No disagreements with the outgoing auditor were reported regarding accounting principles or auditing scope.
Jupiter Neurosciences, Inc. received a notice from Nasdaq informing the company it is in non-compliance with the minimum bid price requirement of $1.00 per share. The company has been granted a 180-day grace period to regain compliance.
🚩 Red Flags
- Delisting notice from Nasdaq regarding minimum bid price requirement.
- Potential for delisting if compliance is not met by September 17, 2025.
- Significant downward pressure on stock price indicated by the 30-day deficiency period.
📋 Key Facts
- Received Nasdaq Notice on March 21, 2025.
- Non-compliance due to failure to maintain a minimum bid price of $1.00 per share (Nasdaq Listing Rule 5550(a)(2)).
- Deficiency period: The stock failed the requirement for 30 consecutive business days between February 6, 2025, and March 20, 2025.
- Compliance deadline: The company has until September 17, 2025, to regain compliance.
- Requirement to regain compliance: Bid price must be at least $1.00 for a minimum of 10 consecutive business days.
Jupiter Neurosciences, Inc. has entered into a new Scope of Work (SOW) with Titan Advisory Services LLC for the 2025 calendar year. This agreement continues a long-standing arrangement where services, including CFO duties performed by Saleem Elmasri, are provided through an intermediary entity rather than direct employment.
🚩 Red Flags
- Related-party transaction: The company is paying a third-party entity (Titan Advisory Services LLC) for executive-level functions (CFO services).
- Complex compensation structure: The arrangement involves shifting monthly fees and discretionary equity/cash bonuses, which can obscure true executive compensation costs.
- History of fee adjustments: Previous agreements involved significant reductions in fees based on capital raising milestones, indicating potential cash flow volatility or dependency on external funding to maintain management services.
📋 Key Facts
- The Company executed a new SOW with Titan Advisory Services LLC on December 17, 2024.
- Titan will be paid a monthly fee of $20,000 for the 2025 calendar year ($240,000 annually).
- The agreement includes provisions for cash bonuses and additional equity compensation at the Company's discretion.
- Saleem Elmasri has been providing CFO services via Titan since January 1, 2023.
Jupiter Neurosciences, Inc. entered into a Strategic Services Agreement with Dominant Treasure Health Company Limited to facilitate product development and distribution in Southeast Asian markets. The agreement includes a $2.3 million upfront payment and contingent success fees based on regional distribution deals.
🚩 Red Flags
- Significant cash outflow ($2.3M) for a micro-cap company to secure market access
- Contingent liabilities (5% success fees and royalties) could impact long-term margins in the target regions
📋 Key Facts
- Agreement Date: December 15, 2024
- Counterparty: Dominant Treasure Health Company Limited
- Upfront Payment: $2,300,000 one-time payment to Dominant Treasure
- Success Fee (Distribution): 5% of any upfront and/or milestone payments for deals in China (incl. HK), Singapore, and Malaysia
- Success Fee (Royalties): 5% of any royalty payments received by the Company
- Term: 36 months, terminable upon mutual agreement
Jupiter Neurosciences, Inc. completed a firm commitment initial public offering of 2,750,000 shares at $4.00 per share, raising approximately $11 million in gross proceeds. The funds are primarily intended for Phase II clinical trials and debt repayment.
🚩 Red Flags
- Significant portion of proceeds allocated to 'repayment of debt' rather than purely growth-oriented activities.
- High underwriting costs including a 7% discount plus an additional 1% expense allowance.
📋 Key Facts
- Offered 2,750,000 shares of Common Stock at a public offering price of $4.00 per share.
- Underwriter (Dominari Securities LLC) received a 7% discount ($3.72 net purchase price per share).
- Total gross proceeds: $11,000,000; Total net proceeds: approximately $9,500,000.
- Offering closed on December 4, 2024.
- Use of proceeds includes funding Phase II clinical trials for JOTROL™ (Parkinson’s Disease), strategic service agreements in SE Asia, R&D, license fees to Aquanova AG, and debt repayment.
Jupiter Neurosciences, Inc. has entered into a Tenth Amendment to extend the maturity date of two senior secured notes from November 15, 2024, to December 11, 2024. The amendment involves interest payments and is contingent upon the company securing a 'Qualified Offering' of at least $8 million.
🚩 Red Flags
- Imminent liquidity pressure: The company is negotiating short-term extensions (less than 30 days) to avoid default.
- Debt maturity wall: Significant senior secured debt is due in less than one month.
- Dependency on a 'Qualified Offering': The company's ability to meet its obligations appears heavily reliant on raising at least $8M in the very near term.
📋 Key Facts
- Maturity date for Puritan Note ($1,111,111.11) and Assigned Note ($266,667) extended from Nov 15, 2024, to Dec 11, 2024.
- Interest of $9,259 on the Puritan Note is due immediately upon execution of the amendment.
- A 'Qualified Offering' is defined as a financing resulting in at least $8,000,000 in cumulative aggregate proceeds.
- If a Qualified Offering occurs before Dec 11, 2024, interest on both notes becomes due immediately.